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Risedronate is a heterocyclic orally active aminobis-
phosphonate and it belongs to the bisphosphonate cat-
egory: these drugs are powerful bone resorption in-
hibitors, thanks to their affinity for hydroxyapatite crys-
tals at bone mineral matrix level and to their inhibiting
effects on osteoclast activity, using the ability of in-
hibiting enzyme FPPS. Recent observations have re-
ported that risedronate can decrease resorption entity,
not only of the trabecular bone, but also of the cortical
bone, modifying therefore the (bone compact) thick-
ness and the cortical porosity entity, which is largely
responsible of femoral fracture especially among elder-
ly patients. Various controlled studies have proved the
efficacy of risedronate in reducing fragility fracture risk
significantly. In particular, it is able to lower in a very
significant way the incidence of vertebral, non-vertebral
and femoral fractures, with precocity of effects after on-
ly six months of therapy. The extension of protocols,
moreover, has marked its efficacy even after seven
years of treatment. Under the metabolic profile, these
studies have also shown that risedronate activity can
reduce bone resorption markers and increase bone
density values at lumbar and femoral level. Results
emerged from a group of women aged over 80 are rele-
vant: risedronate has proved capable of decreasing
femoral fracture risk. Also in male and steroidal osteo-
porosis, clinical controlled studies have shown that
risedronate is effective in decreasing vertebral fracture
incidence. Lastly, tolerability: the main side effects
concern the gastrointestinal tract and they are usually
rare, of minor entity and can be solved by sospending
the treatment. Acute phase reaction is rare, due to rise-
dronate oral administration; it is also valid for os-
teonecrosis of the jaw and atypical fractures.
KEY WORDS: osteoporosis; bisphosphonates; risedronate; fractures; osteo-
clasts.
Mechanism of action
Risedronate is a heterocyclic orally active aminobisphospho-
nate (amino-BF). It belongs to the bisphosphonate category
(BF), molecules discovered at the end of the ’60s and struc-
tural analogues of inorganic pyrophosphate, a substance
present in body fluids that prevents soft tissue calcification
and plays a regulatory role in bone mineralization processes.
BFs take their name after the presence of two carbon-phos-
phorus bonds and are currently used as first-choice drugs in
the treatment of various bone metabolism diseases, such as
osteoporosis, Paget’s disease, bone metastases, etc. (1).
These drugs are powerful inhibitors of bone resorption,
which is the mechanism at the basis of costant skeletal tis-
sue turnover, known as remodeling. Bisphosphonate classic
pharmacological effects are the result of their affinity for hy-
droxyapatite crystals at bone mineral matrix level and also of
their inhibiting effects on osteoclast activity. In terms of an-
tiresorptive ability, risedronate is characterized by a relative
potency 2000 times higher than etidronate, which represents
the reference bisphosphonate (Figure 1): compared to other
BFs, only zoledronic acid, which is solely administered by
venous infusion, has a higher biological relative potency. It
has been demonstrated that bond ability at the matrix differs
among various BFs and affect drug distribution at bone level,
their potency and duration of action (2). The antiresorptive
effect of heterocyclic amino BFs and therefore of risedronate
is linked to the ability of inhibiting enzyme FPPS at osteo-
clastic level, key element of mevalonate cascade that leads
to isoprenoid lipids production, used for post-translational
modification of small GTP-binding proteins essential to os-
teoclast function.
As for other similar compounds, risedronate inhibits selec-
tively bone resorption induced by osteoclasts (3). After oral
administration, around 50% of absorbed share (it’s a very
low percentage because of poor bioavailability) sets on
bones, where it stays for several weeks, whereas the rest is
removed with urine within 24 hours and is intact because
Mini-review
Figure 1 - Molecular structure and biological potency of bisphos-
phonates (modified from Drake MT, 2008).
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risedronate, as all bisphosphonates, is not metabolized.
Risedronate presents a profile with great potential for inhibi-
tion of enzyme FPPS and moderate binding affinity for bone:
among molecules, risedronate is one of strongest FPPS in-
hibitors, along with zoledronic acid (1, 2). On the contrary, as
for the ability of interaction with hydroxyapatite crystals at
mineral matrix level, risedronate has a significantly lower
binding affinity compared to zoledronic acid and alendronate.
Available information on binding ability between hydroxyap-
atite and risedronate, compared to other BFs suggest that al-
so at saturation, risedronate attaches to hydroxyapatite sur-
face to a lesser extent than alendronate, ibandrobate and
zoledronic acid (1). This diminished binding activity gives
risedronate the ability to best respect bone tissue quality,
without interfering with antiresorptive activity (4). Rise-
dronate is indeed effective with every kind of fracture, even
though it reduces bone turnover to a lesser extent compared
to other BFs. This apparent paradox is another example of
the complex relationship between bone turnover reduction
and anti-fracture efficacy. Risedronate effects, especially in
terms of non-vertebral fractures, can be explained by the fact
that less affinity with mineral matrix enables the compound
to have a wider distribution inside bones and a better
achievement of every area, including cortical region and os-
teocyte net (5). Recent researches give osteocytes a funda-
mental role in the regulation of metabolic turnover mecha-
nism. Discover of osteocytes controlling bone formation
through sclerostin secretion allowed to state that osteocytes
can actually stimulate cellular precursors in bone marrow. In
addition, osteocytes can stimulate osteoclast recruitment
and activity through the activation of RANKL system. This
complex mechanism happens thanks to the presence of a
thick lacunar-canicular net, characteristic of osteocytes,
which is predominantly set by mechanical loading (6). Rise-
dronate strong inhibiting action in cellular sites is at the basis
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of its rapid anti-fracture action (2). Another important consid-
eration in terms of reduction of remodeling activity comes
from recent observations, showing that the drug can de-
crease resorption entity, not only of the trabecular bone, but
also of the cortical one, modifying therefore compact bone
thickness, which is largely responsible of femoral fracture
specifically among elderly patients (7). In particular, rise-
dronate has proven to be able to positively modify, in women
over 55, total and cortical volumetric BMD at distal radius
and distal tibia level, reducing at the same time specific corti-
cal porosity indexes (cortical porosity, internal and external
transitional zone porosity) (Figure 2). In this perspective, us-
ing three-dimensional microCT, it is possible to show
through bone biopsies in women who suffer from post-
menopausal osteoporosis that risedronate can decrease
number and dimensions of intracortical cavities, reducing
therefore bone remodeling and consequently non-vertebral
fracture risk, thanks to bone resistance maintenance (8).
Clinical efficacy
In postmenopausal osteoporosis, many random controlled
and double-blind studies have proven risedronate ability to
increase bone mineral density (BMD). In a trial conducted on
111 non- osteoporotic women in early menopause (average
age: 51), risedronate (5 mg/die) increased after two years
bone vertebral density of 1.4% and 2.6% femoral trochanteris
level, against a diminution in both sites observed in placebo
group. After one year of treatment suspension, vertebral
bone density was 2.3% lower compared to baseline in
women who had previously taken risedronate, against a
5.6% diminution in those treated with placebo (9). At a 30 mg
weekly dosage in women with osteoporosis or osteopenia,
risedronate has shown an increase of 5.7% and 2.9% re-
spectively at lumbar and femoral level, after 12 months (10).
In a further study conducted on 543 postmenopausal patients
with bone vertebral density of 2 DS below average and treat-
ed with risedronate (2.5 or 5 mg/day) or with placebo, after 2
years vertebral bone mass rised by 4% compared to initial
levels in women treated with 5 mg/day of risedronate and by
1.4% in those treated with 2.5 mg/day, against no registered
variation in placebo group (11). It is known that the main end-
point in the study of drugs used in osteoporosis treatment is
the ability of reducing fragility fracture risk significantly. For
this reason, specific random and double-blind studies have
been conducted, aiming to specifically assess risedronate ef-
ficacy in decreasing osteoporotic fracture incidence, com-
pared to placebo. In a multicenter trial, 939 postmenopausal
women (average age: 69) with reduced bone density (-2 DS
below average) and a past vertebral fracture completed the
three-year risedronate treatment (5mg/day): at the end, cu-
mulative incidence of new vertebral fractures was of 11.3% in
patients treated with risedronate, compared to 16.3% in
those assigned to placebo group, with a reduction of relative
risk of 41%, whereas non-vertebral fracture incidence was re-
spectively of 5.2% against 8.4% and a reduction of relative
risk of 39% (12). It is to report that precocity of anti-fracture
effect of risedronate in this trial, with a reduction of relative
risk for vertebral fractures of 65%, after 12 months of treat-
ment. An analogue study conducted in Europe and Australia
on 1226 patients suffering from full-blown osteoporosis con-
firmed risedronate efficacy, showing a significant reduction of
relative risk of 49% for new vertebral fractures (13). In addi-
Figure 2 - Microstructural effects of risedronate in osteoporotic
women aged over 55.
a: total volumetric BMD; b: cortical volumetric BMD; c: total cortical
porosity; d: external cortical porosity; e: internal cortical porosity; f:
volumetric trabecular BMD (modified from Bala Y, 2014).
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tion, a subsequent sub-analysis of this study confirmed pre-
cocity of anti-fracture effect of risedronate, with a statistically
significant difference already after 6 months, compared to
placebo group, proving a reduction of relative risk for verte-
bral fractures of 69% after 12 months (Figure 3) (14). Data
confirmed also in non-vertebral fractures, where, compared
to statistically significant difference already after 6 months,
incidence of non-vertebral fractures decreased of 74% in the
group of patients on risedronate treatment (15). In both trials,
risedronate was administered along with calcium and vitamin
D just like placebo and proved to be able to increase mineral
density at lumbar and femoral level significantly, and at the
same time to reduce bone resorption markers (12, 13). It
emerges from a comparative analysis of random controlled
studies conducted on bisphosphonates oral administered for
osteoporosis therapy that both risedronate and alendronate
can reduce incidence of vertebral, femoral and non-vertebral
fractures significantly, in contrast to what happens for iban-
drobate, whose clinical anti-fracture efficacy emerges solely
for vertebral fractures (16). As shown in Figure 4, risedronate
can significantly decrease relative risk (RR) for vertebral and
non-vertebral fractures (-49% and -39% respectively); the
same thing happens for alendronate as well, even if in small-
er numbers (-47% and -20%), whereas it doesn’t happen for
ibandrobate (17).
As for long-term efficacy and tolerability, in a first study de-
signed like an extention of a previous trial lasted 3 years, it
was possible to observe in 220 women that the risk of new
vertebral fractures decreased even more (-59%) during 4th
and 5th year in randomized group with risedronate treatment
(18): furthermore, increase of vertebral and femoral bone
mineral density and reduction of bone turnover markers ob-
served at 3rd year were confirmed at 5th year. Another study
conducted for 7 years confirmed long-term anti-fracture effi-
cacy of the drug, showing that annual incidence of new ver-
tebral fractures in patients treated with risedronate does not
statistically differ from previous period, in conjunction with an
excellent profile of tolerability (19). It is appropriate to notice
that, despite extended periods of use, residronate did not in-
duce to significant modifications of parameters linked to
bone tissue quality. In a first histomorphometric analysis
conducted after 3 years in fact, along with a significant re-
duction of remodeling indexes, no difference emerged com-
pared to control group as for structural parameters, such as
BV/TV, Ct.Th, Ct.Por, Tbn, Tb.Sp, Tb.Th (20). A further
study conducted after 5 years of treatment using micro-CT
allowed to appreciate bone volume and trabecular architec-
ture maintenance, in conjunction with mineralization degree
maintenance (21).
In a post-hoc analysis, in which data from three-year VERT
studies were compared to results obtained from residronate
dose of 35 mg weekly, risk of new vertebral fractures de-
creased after 1 year of 71% compared to placebo, by just
more of what observed in the two VERT studies (61-65%)
(22). In order to validate efficacy and tolerability of rise-
dronate weekly administrated, a study conducted on a total
of 1,456 women aged = / > 50, in postmenopause for 5
years, with reduced bone mineral density (lumbar or femoral
T-score < / = 2.5 or T-score < 2 and at least one vertebral
fracture), comparing 3 dosing schedules (risedronate 35 mg
weekly, 50 mg weekly, 5 mg/day in conjunction with calcium
and vitamin D) underlined that three dosing schedules
showed comparable densitometric efficacy after one year of
treatment, without detecting significant differences about in-
cidence of side-effects (23). As for oral monthly administra-
tion in order to optimize adherence to the treatment, a com-
parative study between 150 mg monthly vs 5 mg/day was
conducted: after one year, increase of two formulas was sub-
stantially similar (+3.5% vs +3.4%), underlining efficacy of
monthly formula through statistical analysis of non-inferiority
(24). Results from spontaneous observational studies are
very interesting. In a retrospective study conducted on more
than 33,000 patients aged over 65 aiming to analyze inci-
dence of non-vertebral and femoral fractures specifically af-
ter 12 months of risedronate and alendronate treatment, has
proven that cohort of patients treated with risedronate had a
marked and precocious reduction of non-vertebral fracture
incidence (19% and 18% after 6 and 12 months, respective-
ly) compared to the group in therapy with alendronate: in
particular for femoral fractures, reduction already reached
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Figure 3 - Precocity of anti-fracture effect of risedronate (6 months)
expressed as relative risk (RR) reduction (modified from Roux C,
2004).
Figure 4 - Reduction of relative risk (RR) of vertebral fracture (up)
and non-vertebral (down) in women with postmenopausal osteo-
porosis after three years of therapy with bisphosphonates, oral ad-
ministration (modified from Boonen S, 2007).
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46% after 6 months and it remained so even at the end of
observation period (43% after 12 months) (25). More recent-
ly, another observational study, lasted 2 years and conduct-
ed on osteoporotic women aged over 65, compared weekly
treatment of risedronate and alendronate and could show
that both treatments led to a reduction of incidence of
femoral and non-vertebral fractures after 24 months, respec-
tively of 45% and 30% (26). Data analysis after 6 and 12
months allowed nevertheless to point out that risedronate
has a more premature ability of reducing incidence of both
femoral and non-vertebral fractures (Figure 5).
Data published in relation to osteoporosis management in el-
derly population are very interesting. A recent publication on
this point underlined the importance of nutritional factors, in
particular of calcium, vitamin D and proteins in preventing
falls and it specifically identifies as major cause of inade-
quate prescribed medications, the perception that a long-
term therapy is necessary in order to get an effective answer
in terms of reduction of fracture risk. It is remarked how in
the age group over 80, data are largely available, indicating
that efficacy and safety of osteoporotic drugs are essentially
excellent, identifying in poor adherence the main factor of a
successful treatment (27). As for risedronate efficacy specifi-
cally, a post-hoc analysis of data obtained from pivotal stud-
ies allowed to appreciate the fact that after one and three
years incidence of new vertebral fractures was of 2.5% and
10.9% in risedronate group and of 18.2% and 24.6% in con-
trol group, with a reduction of relative risk of 81% and 44%
(28). Beside this important fact, it means that after just one
year of treatment with risedronate, risk of new vertebral frac-
tures in elderly people reduced of 81%; authors point out
that NNT (Number Needed to Treat) is just 12 after 12
months, and it turns to 16 at the end of the three-year period.
NNT indicates number of patients to treat in order to reduce
of one unit a pathological event and therefore it indirectly
evaluates theraupetic ability of drugs. As for risedronate, re-
sults of the study underline that it is necessary to treat only
12 patients during one year to get a reduction of a new ver-
tebral fracture event, emphasizing efficacy and precocity of
effect of the drug.
Another controlled study, specifically aimed at evaluate rise-
dronate efficacy in elderly population, was conducted on a
wide cohort of patients (5,445 women with full-blown osteo-
porosis, aged between 70 and 79). Results obtained after 3
years of treatment proved that incidence of new femoral frac-
tures was of 1.9% in patients who had taken risedronate (2.5
mg/day or 5 mg/day) against 3.2% in those treated with
placebo, with a reduction of fracture risk of 41% and a statis-
tically significant difference (29). In addition, always in the
same study, in a population of patients aged over 80 select-
ed on a basis of a risk factor unlinked to bone mineral densi-
ty (history of a recent fall, for example), incidence of femoral
fracture was lower in the group treated with risedronate,
compared to placebo group (4.2% vs 5.1%).
We have already discussed that from a pathophysiologic
point of view recent studies have shown that risedronate
slows microstructural deterioration at remodeling unit level
(BMU) in women right after menopause, whereas in elderly
women it acts so that it reduces BMU number (7, 8). Well,
these histomorphometric data represent the rational basis of
drug clinical efficacy: risedronate ability of reducing the num-
ber of intracortical cavities and therefore porosity in patients
suffering from involutional osteoporosis ensures a better re-
sistance and a reduction of fracture risk in elderly people, al-
ways respecting bone quality.
Osteoporosis therapy provides not only usage of antiresorp-
tive drugs such as bisphosphonates, but also drugs charac-
terized by a stimulating action on osteoblastic component
and therefore on neoplasm, like teriparatide. In many occa-
sions it is appropriate to rotate these two treatments, with the
aim of optimize the effect on fracture risk. It has been proven
that anabolic answer to teriparatide can be attenuated or de-
layed in patients previously treated with alendronate, able to
markedly affect resorption mechanisms. A study, which was
designed with the aim of monitoring response after a previ-
ous antiresorptive treatment, showed a more precocious an-
swer of neoplasm markers after only 3 months in group of
pre-treatment with risedronate, compared to the one with al-
endronate, with a significant increase of lumbar BMD after
12 months (5.1% vs 3.6%, p < 0.05) and of trabecular spine
content with QCT (24.1% vs 13.7%, p < 0.05) (30, 31).
Male osteoporosis is a primitive form of multifactorial patho-
genesis disease, in which increase of fracture risk is linked
to an acceleration of osteoclast activity and to a lesser extent
to a reduced osteoblast formation activity. Risedronate has
proven to be effective even in this variety of osteoporosis. In
a group of 316 men suffering from primitive and secondary
osteoporosis, the drug produced an increase of lumbar and
femoral BMD of 6.6 vs 2.2% and 4.4 vs 0.4% respectively af-
ter 2 years, compared to control group (32), with a reduction
of fracture risk of 61% for new vertebral fractures and of 47%
for non-vertebral fractures. In a study lasted 2 years, lumbar
BMD increased after 12 and 24 months of 4.6% and 4.5% re-
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Figure 5 - Cumulative curves concerning incidence of non-vertebral
(up) and hip (down) fractures in patients suffering from osteoporo-
sis and in treatment with risedronate (dashed line) or alendronate
(dotted line) compared to a control group (modified from Lindsay R,
2013).
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spectively, compared to placebo and in conjunction with a
significant diminution of metabolic turnover indexes (33). In a
following study, conducted as randomized and double-blind
for the first two years and the next two as an open-label,
risedronate at 35mg weekly dose promoted a lumbar BMD
increase of 7.87% in the group treated for 4 years, and of
6.25% in the group that had placebo for the first 2 years and
risedronate only in the following two (34). In both trials drug
tolerability was excellent, with a full overlap of side-effects
between study group and control group. Data from usage of
risedronate in secondary male osteoporosis are interesting
(35): positive results in terms of BMD increases were found
in patients suffering from secondary osteoporosis to stroke,
hyperthyroidism, inflammatory bowel diseases and post-
transplant.
Steroid osteoporosis is a secondary variety of osteoporosis,
of complex pathogenesis, in which predominates an increase
of bone resorption processes, emphasis of bone mineraliza-
tion and increase of fracture risk. Two clinical, controlled with
placebo, randomized and double-blind trials, lasting one
year, proved efficacy of risedronate (2.5 mg/day or 5
mg/day) in prevent loss of vertebral bone mass induced by
corticosteroid therapy at high dose (>/= 7.5 mg/day of pred-
nisone or equivalent compounds) for protracted periods (> 3
months) in 514 patients, both men and women (36-38). A
third study, lasted 2 years and conducted on 120 women in
post-menopause with rheumatoid arthritis, who took pred-
nisolone at doses above 2.5 mg/day, confirmed risedronate
ability of preserving bone mineral density in patients in pro-
tracted corticosteroid treatment (39). Furthermore, rise-
dronate induced positive effects also in men with steroid os-
teoporosis.
As for skeletal involvement for malignant disorders, a multi-
center, randomized, open-label study in fase II/III evaluated
potential advantage of adding risedronate to docetaxel in pa-
tients with metastatic prostatic neoplasia, resistant to surgi-
cal castration. This study proved that adding risedronate to
docetaxel in these patients, even if well tolerated, did not
have any effect on disease progression, PSA levels, re-
sponse to pain and survival (40). On the contrary, LHRH-ag-
onist treatment for advanced prostate tumor produces an in-
crease of bone turnover and a fast bone loss within the first
6 months of therapy, and it can be prevented thanks to
weekly treatment with risedronate (41). In women in post-
menopause at risk of fragility fracture in adjuvant treatment
with aromatase inhibitors, such as anastrozole for breast
neoplasia with receptors for estrogen receptor positive, addi-
tion of therapy with risedronate 35 mg/weekly induce a sig-
nificant bone mass increase, both at spinal level and femoral
one up to 24 months (42).
Risedronate is in general well tolerated. The main side effects
concern the gastrointestinal tract: dyspepsia, abdominal pain,
gastritis and oesophagitis. Also reported: headache, muscu-
loskeletal pain, rarely glossitis, edemas, skin rashes. During
clinical studies conducted on patients suffering from Paget’s
disease, treated with risedronate 30 mg/day, three cases of
iritis were reported. In some patients treated with rise-
dronate a slight and transient diminution of serum levels of
calcium and phosphate was observed: rare cases of abnor-
mality in hepatic cytolysis tests were reported. Use of rise-
dronate is however contraindicated in patients with hypocal-
caemia, known hypersensitivity to a product component, in-
ability of standing or sitting upright for at least 30 minutes,
oesophagus disorders that lead to delayed oesophageal
emptying, such as stenosis or achalasia, renal creatinine
clearance < 30 ml/minute (43). As for risedronate, symptoms
of “acute phase-like” reaction generally appear within 5 days
from first dose intake. In comparative studies with rise-
dronate 75 mg, 2 tablets monthly vs risedronate 5 mg/day,
incidence of acute phase reactions was 7.6% of patients,
compared to 3.6% respectively and duration of symptoms
was 7 days maximum (34, 43). In clinical controlled studies
conducted on women in post-menopause with osteoporosis,
incidence of adverse events was similar to the group treated
with risedronate, compared to placebo. In a combined analy-
sis of 9 clinical studies, in which risedronate was once daily
administered, incidence of adverse events of upper gastroin-
testinal tract was similar to patients randomized with rise-
dronate and those treated with placebo; no significant differ-
ence emerged between risedronate 5 mg once daily and
risedronate 35 mg once weekly as for adverse events of up-
per gastrointestinal tract (18, 19, 43). In recent years, report
in literature of possible association between bisphospho-
nates and osteonecrosis of the jaw (ONJ) raised interest. Al-
though many publications on BFs and ONJ have been pro-
duced, there are no prospective studies that prove that bis-
phosphonates substantially help pathogenesis of this condi-
tion. Even if some authors suggested that oral bisphospho-
nates can cause ONJ in patients with osteoporosis, data are
very conflicting to date. In fact, recent meta-analysis indicate
BFs use for osteoporosis is associated to ONJ incidence,
lower than 1 on 100,000 patients every year of exposure
(44). Another adverse event that has been linked to extend-
ed treatment with bisphosphonates is the occurrence of
atypical diaphyseal subtrochanteric fractures. However,
there are no sure facts about a possible link between use of
risedronate and occurrence of subtrochanteric fractures
(45). Efficacy and safety of risedronate in patients with renal
impairment have been evaluated in a retrospective analysis
that used data from 9 clinical trials (43). Incidence of verte-
bral fractures was significantly lower in patients treated with
risedronate, compared to placebo group, for all sub-groups
of renal impairment (mild, moderate, severe). Incidence of
vertebral fractures in patients treated with risedronate was
similar among various groups of renal impairment, whereas
in patients treated with placebo, incidence of fracture in-
creased along with the degree of renal dysfunction. Fre-
quency of adverse events and renal adverse events linked
to organ function was similar in placebo group and rise-
dronate (5 mg/day) independently of blood creatinine values.
A more recent retrospective analysis evaluated influence of
different dosages (5 and 15 mg daily, 35 and 50 mg weekly,
75 mg 2 tablets monthly) of risedronate on renal function in
patients with or without baseline renal impairment or risk
factors without observing significant differences among
groups (46).
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